OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors

By Elizabeth S. Eaton | Jan 12, 2018 | 6:13 PM GMT

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said IV rosmantuzumab (OMP-131R10) every two weeks

Read the full 116 word article

How to gain access

Continue reading with a
two-week free trial.